Editas Medicine (EDIT) Tops Q4 EPS by 36c

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.23), $0.36 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $60.04 million versus the consensus estimate of $3.7 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• AeroVironment restates quarterly financials, citing $89M goodwill error